1. Home
  2. BWAY vs CVRX Comparison

BWAY vs CVRX Comparison

Compare BWAY & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWAY
  • CVRX
  • Stock Information
  • Founded
  • BWAY 2003
  • CVRX 2000
  • Country
  • BWAY Israel
  • CVRX United States
  • Employees
  • BWAY N/A
  • CVRX N/A
  • Industry
  • BWAY Medical/Dental Instruments
  • CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • BWAY Health Care
  • CVRX Health Care
  • Exchange
  • BWAY Nasdaq
  • CVRX Nasdaq
  • Market Cap
  • BWAY 201.1M
  • CVRX 174.4M
  • IPO Year
  • BWAY 2019
  • CVRX 2021
  • Fundamental
  • Price
  • BWAY $10.96
  • CVRX $5.89
  • Analyst Decision
  • BWAY Strong Buy
  • CVRX Buy
  • Analyst Count
  • BWAY 2
  • CVRX 7
  • Target Price
  • BWAY $14.25
  • CVRX $14.50
  • AVG Volume (30 Days)
  • BWAY 33.7K
  • CVRX 236.3K
  • Earning Date
  • BWAY 08-05-2025
  • CVRX 07-28-2025
  • Dividend Yield
  • BWAY N/A
  • CVRX N/A
  • EPS Growth
  • BWAY N/A
  • CVRX N/A
  • EPS
  • BWAY 0.08
  • CVRX N/A
  • Revenue
  • BWAY $43,457,000.00
  • CVRX $52,870,000.00
  • Revenue This Year
  • BWAY $351.53
  • CVRX $11.53
  • Revenue Next Year
  • BWAY $21.84
  • CVRX $18.61
  • P/E Ratio
  • BWAY $54.48
  • CVRX N/A
  • Revenue Growth
  • BWAY 26.86
  • CVRX 25.62
  • 52 Week Low
  • BWAY $5.67
  • CVRX $4.30
  • 52 Week High
  • BWAY $12.00
  • CVRX $18.55
  • Technical
  • Relative Strength Index (RSI)
  • BWAY 58.38
  • CVRX 41.15
  • Support Level
  • BWAY $10.81
  • CVRX $5.54
  • Resistance Level
  • BWAY $11.40
  • CVRX $5.96
  • Average True Range (ATR)
  • BWAY 0.46
  • CVRX 0.40
  • MACD
  • BWAY -0.03
  • CVRX -0.03
  • Stochastic Oscillator
  • BWAY 50.88
  • CVRX 21.99

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

About CVRX CVRx Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Share on Social Networks: